INTRESO
20.6.2024 08:01:34 CEST | Business Wire | Press release
International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18].
On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical.
INTRESO Group produces BLUEFUME™, a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride. BLUEFUME™ is the latest iteration of a tried and tested chemical, HCN, successfully used around the world for decades. INTRESO Group’s product is fully approved in numerous markets including in the EU, UK, Australia, New Zealand, Malaysia, Morocco and South Africa. Most recently, it has been put through rigorous testing and approval processes in Australia in 2023, with subsequent regulatory approval demonstrating impressive results against the latest standards.
Effective and economical, BLUEFUME™ breaks down into naturally occurring substances, meaning it also has a far lower environmental footprint than sulfuryl fluoride.
Besides being a Biocidal Product, sulfuryl fluoride is also a Plant Protection Product for the treatment of tree logs exported from the EU. In which case, additionally, INTRESO Group’s proprietary product, Ethanedinitrile (EDN™), is a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride and has already been approved for the fumigation of timber and wood products in countries including Australia, New Zealand, South Korea, Malaysia, Uruguay, South Africa and Turkey. EDN was also successfully used over successive years in the Czech Republic under emergency use authorization during their recent bark beetle outbreak. This demonstrates that other major agricultural exporters have moved faster than the EU in approving alternative chemicals which adhere to stringent modern safety and environmental standards.
Commenting on the potential new restrictions on the use of sulfuryl fluoride in the EU, Kade McConville, Executive Director of INTRESO Group said:
“The claims that there is no available and highly effective alternative to sulfuryl fluoride for biocidal and plant protection use are simply not true. Our products, including EDN™ and BLUEFUME, are drop-in replacements that have been shown to be efficient under a wider set of climatic conditions than sulfuryl fluoride.
With increasing evidence as to the harms to human health and the planet resulting from sulfuryl fluoride, it is vitally important that EU decision-makers consider and understand the fact that alternative solutions are readily available for use in European fumigation, and that whilst sulfuryl fluoride is a tool, it is not the only tool in the toolbox.
Ahead of this pivotal vote, I have written to the Commission to make clear that our innovative, environmentally sustainable solutions already provide an effective alternative to sulfuryl fluoride in forward-thinking countries with some of the strictest biosecurity standards, including Australia and New Zealand.”
Background
- Fumigation is essential to protect against risks of invasive pests from international trade in raw commodities, with Europe facing unprecedented levels of bark beetle breakouts in conifer forests1.
- Sulfuryl fluoride, the most widely used fumigant in the EU, has a Global Warming Potential (GWP) more than 4500 times that of carbon dioxide.
- Use of sulfuryl fluoride is increasingly globally.
- Negotiations on the EU’s F-Gas Regulation, adopted in March 2024, resulted in new monitoring and recapture requirements and considered a total ban.
- EDNTM has a GWP over 4400x lower than sulfuryl fluoride.
- For more information on INTRESO: www.intreso.com
| ____________________ | |
1 |
https://foresteurope.org/bark-beetle-outbreaks-in-forests-a-pan-european-view/ |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619174501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
